Unicycive Therapeutics Files 8-K for 'Other Events'

TL;DR

**Unicycive Therapeutics filed an 8-K for 'Other Events' on Feb 21, 2024, but the details aren't in this snippet.**

AI Summary

Unicycive Therapeutics, Inc. filed an 8-K on February 21, 2024, under the 'Other Events' category. The filing indicates a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. No specific financial transactions, new agreements, or material events beyond the filing itself are detailed in the provided excerpt.

Why It Matters

This filing signals that Unicycive Therapeutics, Inc. has an event to report, though the provided text does not specify the nature of that event, leaving investors to await further details.

Risk Assessment

Risk Level: low — The filing itself is a standard regulatory disclosure and the provided text does not contain information indicating any immediate financial or operational risk.

Key Players & Entities

• Unicycive Therapeutics, Inc. (company) — Registrant company filing the 8-K
• February 21, 2024 (date) — Date of earliest event reported and filing date
• 001-40582 (other) — Commission File Number
• Delaware (other) — State of incorporation
• 4300 El Camino Real, Suite 210 Los Alto, CA 94022 (other) — Principal executive offices address

FAQ

Key Financial Figures

• $35 million — n Stock"), had closed below the minimum $35 million requirement for continued listing on th
• $1.00 — ess days , had closed below the minimum $1.00 per share and, as a result, the Company
• $1.00 m — e Company is not in compliance with the $1.00 minimum bid price requirement (the "Minim

Filing Documents

• ea0200428-8k_unicyc.htm (8-K) — 23KB
• 0001213900-24-015753.txt ( ) — 194KB
• uncy-20240221.xsd (EX-101.SCH) — 3KB
• uncy-20240221_lab.xml (EX-101.LAB) — 33KB
• uncy-20240221_pre.xml (EX-101.PRE) — 22KB
• ea0200428-8k_unicyc_htm.xml (XML) — 4KB

01

Item 8.01 Other Events. As previously disclosed, on September 19, 2023, Unicycive Therapeutics, Inc. (the "Company") received written notification (the "Notice") from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") indicating that, for the last thirty consecutive business days, the market value of the Company's Common Stock (the "Common Stock"), had closed below the minimum $35 million requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the "Minimum Market Value Requirement"). In addition, on September 19, 2023, the Company received a Notice from Nasdaq indicating that the bid price for the Common Stock, for the last 30 consecutive business days for the last thirty consecutive business days , had closed below the minimum $1.00 per share and, as a result, the Company is not in compliance with the $1.00 minimum bid price requirement (the "Minimum Bid Price Requirement") for the continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2). On February 21, 2024, the Company received a letter from Nasdaq that the Company has regained compliance with the Minimum Market Value Requirement and the Minimum Bid Price Requirement and the matters are now closed. . SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: February 21, 2024 UNICYCIVE THERAPEUTICS, INC. By: /s/ Shalabh Gupta Shalabh Gupta Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR